Clinical Trials Logo

Polymyositis clinical trials

View clinical trials related to Polymyositis.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06383819 Completed - Fibrosis Clinical Trials

Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19

Start date: April 8, 2022
Phase: Phase 3
Study type: Interventional

The goal of this clinical study is to evaluate the efficacy and safety of Longidaza®, lyophilizate for preparation of solution for injection, at a dose of 3000 IU compared to placebo in the treatment of adult patients with residual changes in the lungs after COVID-19 infection

NCT ID: NCT04976140 Completed - Dermatomyositis Clinical Trials

Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis

Start date: December 15, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the maximum tolerated dose (MTD) based on the safety and tolerability after single-dose administration of PN-101 in patients with refractory polymyositis or dermatomyositis. To explore the efficacy after single-dose administration of PN-101 in patients with refractory polymyositis or dermatomyositis.

NCT ID: NCT04628936 Completed - Dermatomyositis Clinical Trials

Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

Start date: November 4, 2020
Phase: Phase 2
Study type: Interventional

This was an open-label study to evaluate the long-term efficacy and safety of KZR-616 in patients with active polymyositis (PM) or dermatomyositis (DM) who completed the double-blind treatment period of Study KZR-616-003, up to and including the Week 32 Visit, prior to the first dose of open-label KZR-616.

NCT ID: NCT04486261 Completed - Dermatomyositis Clinical Trials

High-intensity Strength Training in Myositis

HI-STIM
Start date: August 30, 2021
Phase: N/A
Study type: Interventional

This study evaluates the effects of a high-intensity strength training in patients with myositis with the primary outcome being quality of life (SF-36). The study is designed as a parallel group randomised controlled trial with an intervention group and a control group.

NCT ID: NCT04033926 Completed - Dermatomyositis Clinical Trials

A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis

PRESIDIO
Start date: January 14, 2020
Phase: Phase 2
Study type: Interventional

This was a Phase 2 randomized, double-blind, placebo-controlled, crossover, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with KZR-616 in patients with active polymyositis (PM) or dermatomyositis (DM). Patients were evaluated for eligibility during the Screening Period. Eligible patients were stratified by diagnosis of DM or PM and randomized 1:1 to Arm A or Arm B of the study. During the 32-week treatment period, patients received study drug subcutaneously (SC) once weekly with 2 treatment periods of 16 weeks each. This study was conducted on an outpatient basis.

NCT ID: NCT03941184 Completed - Clinical trials for Rheumatoid Arthritis

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

Start date: January 1, 1995
Phase:
Study type: Observational

This case control study aims to determine whether spontaneous coronary artery dissection (SCAD) is associated with autoimmune diseases and to update the incidence of SCAD in a population-based cohort.

NCT ID: NCT03817424 Completed - Clinical trials for Systemic Lupus Erythematosus

A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

Start date: December 13, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of escalating, multiple subcutaneous (SC) doses of VIB7734 in participants with Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis.

NCT ID: NCT03414086 Completed - Dermatomyositis Clinical Trials

Predictor of Clinical Response to Acthar in Myositis

Start date: November 6, 2017
Phase:
Study type: Observational

Comparing the clinical effects of Acthar Gel before and after treatment and compare it to patients with inactive disease.

NCT ID: NCT02971683 Completed - Dermatomyositis Clinical Trials

Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

Start date: May 4, 2017
Phase: Phase 3
Study type: Interventional

Trial to Evaluate the Efficacy and Safety of Abatacept subcutaneous (SC) in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy

NCT ID: NCT02881450 Completed - Polymyositis Clinical Trials

Epidemiological Study of Inflammatory Myopathies in a French Region

PREMIA
Start date: January 2012
Phase:
Study type: Observational

Knowledge of the descriptive epidemiology of MIs is very limited. The main objective of this study is to determine the prevalence of inflammatory myopathies in Alsace at the 1st January 2012 with "capture-recapture" design using several independent sources of case identification.